The Natural Product Oridonin as an Anticancer Agent: Current Achievements and Problems


Cite item

Full Text

Abstract

Oridonin, an active diterpenoid isolated from traditional Chinese herbal medicine, has received a rising attention for its remarkable roles in cancer therapy. In recent years, increasing evidences have revealed that oridonin inhibits the occurrence and development of tumor cells through multiple mechanisms, including induction of apoptosis and autophagy, cell cycle arrest, and inhibition of angiogenesis as well as migration and invasion. In addition, several molecular signal targets have been identified, including ROS, EGFR, NF-κB, PI3K/Akt, and MAPK. In this paper, we review considerable knowledge about the molecular mechanisms and signal targets of oridonin, which has been studied in recent years. It is expected that oridonin may be developed as a novel anti-tumor herbal medicine in human cancer treatment.

About the authors

Shiying Ye

Institute of Pharmacy and Pharmacology, School of Pharmaceutical Science, Hengyang Medical School, University of South China

Email: info@benthamscience.net

Jinhuan Jiang

Institute of Pharmacy and Pharmacology, School of Pharmaceutical Science, Hengyang Medical School, University of South China

Author for correspondence.
Email: info@benthamscience.net

Xiangyan Hu

Institute of Pharmacy and Pharmacology, School of Pharmaceutical Science, Hengyang Medical School, University of South China

Email: info@benthamscience.net

Sisi Huang

Institute of Pharmacy and Pharmacology, School of Pharmaceutical Science, Hengyang Medical School, University of South China

Email: info@benthamscience.net

References

  1. Abelson, P.H. Medicine from plants. Science, 1990, 247(4942), 513. doi: 10.1126/science.2300807 PMID: 2300807
  2. Abdullah, N.A.; Md Hashim, N.F.; Ammar, A.; Muhamad Zakuan, N. An insight into the anti-angiogenic and anti-metastatic effects of oridonin: Current knowledge and future potential. Molecules, 2021, 26(4), 775. doi: 10.3390/molecules26040775 PMID: 33546106
  3. Owona, B.A.; Schluesener, H.J. Molecular insight in the multifunctional effects of oridonin. Drugs R D., 2015, 15(3), 233-244. doi: 10.1007/s40268-015-0102-z PMID: 26290464
  4. Liu, W.; Huang, G.; Yang, Y.; Gao, R.; Zhang, S.; Kou, B. Oridonin inhibits epithelial-mesenchymal transition of human nasopharyngeal carcinoma cells by negatively regulating AKT/STAT3 signaling pathway. Int. J. Med. Sci., 2021, 18(1), 81-87. doi: 10.7150/ijms.48552 PMID: 33390776
  5. Sobral, P.J.M.; Vicente, A.T.S.; Salvador, J.A.R. Recent advances in oridonin derivatives with anticancer activity. Front Chem., 2023, 11, 1066280. doi: 10.3389/fchem.2023.1066280 PMID: 36846854
  6. Xu, J.; Wold, E.; Ding, Y.; Shen, Q.; Zhou, J. Therapeutic potential of oridonin and its analogs: From anticancer and antiinflammation to neuroprotection. Molecules, 2018, 23(2), 474. doi: 10.3390/molecules23020474 PMID: 29470395
  7. Zhao, X.; Zhang, Q.; Wang, Y.; Li, S.; Yu, X.; Wang, B.; Wang, X. Oridonin induces autophagy-mediated cell death in pancreatic cancer by activating the c-Jun N-terminal kinase pathway and inhibiting phosphoinositide 3-kinase signaling. Ann. Transl. Med., 2021, 9(13), 1084. doi: 10.21037/atm-21-2630 PMID: 34422996
  8. Zhou, J.; Li, Y.; Shi, X.; Hao, S.; Zhang, F.; Guo, Z.; Gao, Y.; Guo, H.; Liu, L. Oridonin inhibits tumor angiogenesis and induces vessel normalization in experimental colon cancer. J. Cancer, 2021, 12(11), 3257-3264. doi: 10.7150/jca.55929 PMID: 33976735
  9. Jin, X.; Xu, J.; Yang, F.; Chen, J.; Luo, F.; Xu, B.; Xu, J. Oridonin attenuates thioacetamide-induced osteoclastogenesis through mapk/nf-κb pathway and thioacetamide-inhibited osteoblastogenesis through BMP-2/RUNX2 Pathway. Calcif. Tissue Int., 2023, 112(6), 704-715. doi: 10.1007/s00223-023-01080-5 PMID: 37032340
  10. Chen, G.; Yang, Z.; Wen, D.; Li, P.; Xiong, Q.; Wu, C. Oridonin inhibits mycobacterium marinum infection-induced oxidative stress in vitro and in vivo. Pathogens., 2023, 12(6), 799. doi: 10.3390/pathogens12060799 PMID: 37375489
  11. Zhang, Z.; Zhang, H.; Zhang, Y.; Zhang, Q.; Liu, Q.; Hu, Y.; Chen, X.; Wang, J.; Shi, Y.; Deng, C.; Gong, P.; Zhang, B.; Li, X.; Zhu, B.; Ye, H. Oridonin inhibits SARS-CoV-2 replication by targeting viral proteinase and polymerase. Virol. Sin., 2023, 38(3), 470-479. doi: 10.1016/j.virs.2023.04.008 PMID: 37127212
  12. Kazantseva, L.; Becerra, J.; Santos-Ruiz, L. Oridonin enhances antitumor effects of doxorubicin in human osteosarcoma cells. Pharmacol. Rep., 2022, 74(1), 248-256. doi: 10.1007/s43440-021-00324-1 PMID: 34427908
  13. Jiang, J.H.; Pi, J.; Cai, J.Y. Oridonin exhibits anti-angiogenic activity in human umbilical vein endothelial cells by inhibiting VEGF-induced VEGFR-2 signaling pathway. Pathol. Res. Pract., 2020, 216(8), 153031. doi: 10.1016/j.prp.2020.153031 PMID: 32703495
  14. Zhao, Y.; Xiao, W.; Peng, W.; Huang, Q.; Wu, K.; Evans, C.E.; Liu, X.; Jin, H. Oridonin-loaded nanoparticles inhibit breast cancer progression through regulation of ros-related nrf2 signaling pathway. Front. Bioeng. Biotechnol., 2021, 9, 600579. doi: 10.3389/fbioe.2021.600579 PMID: 33898397
  15. Gui, Y.; Cheng, J.; Chen, Z. Oridonin improves the therapeutic effect of lentinan on lung cancer. Exp. Ther. Med., 2021, 22(2), 886. doi: 10.3892/etm.2021.10318 PMID: 34194564
  16. Chen, F.; Liao, J.; Wu, P.; Cheng, L.; Ma, Y.; Zhang, L.; Leng, X.; Zhu, X.; Liu, Z.; Xie, F. Oridonin inhibits the occurrence and development of colorectal cancer by reversing the Warburg effect via reducing PKM2 dimer formation and preventing its entry into the nucleus. Eur. J. Pharmacol., 2023, 954, 175856. doi: 10.1016/j.ejphar.2023.175856 PMID: 37321470
  17. Liu, X.; Xu, J.; Zhou, J.; Shen, Q. Oridonin and its derivatives for cancer treatment and overcoming therapeutic resistance. Genes Dis., 2021, 8(4), 448-462. doi: 10.1016/j.gendis.2020.06.010 PMID: 34179309
  18. Yang, J.; Ren, X.; Zhang, L.; Li, Y.; Cheng, B.; Xia, J. Oridonin inhibits oral cancer growth and PI3K/Akt signaling pathway. Biomed. Pharmacother., 2018, 100, 226-232. doi: 10.1016/j.biopha.2018.02.011 PMID: 29432993
  19. Wang, H.; Zhu, L.; Feng, X.; Zhang, H.; Luo, Q.; Chen, F. Oridonin induces G2/M cell cycle arrest and apoptosis in human oral squamous cell carcinoma. Eur. J. Pharmacol., 2017, 815, 282-289. doi: 10.1016/j.ejphar.2017.09.021 PMID: 28935563
  20. Bohanon, F.J.; Wang, X.; Graham, B.M.; Prasai, A.; Vasudevan, S.J.; Ding, C.; Ding, Y.; Radhakrishnan, G.L.; Rastellini, C.; Zhou, J.; Radhakrishnan, R.S. Enhanced anti-fibrogenic effects of novel oridonin derivative CYD0692 in hepatic stellate cells. Mol. Cell. Biochem., 2015, 410(1-2), 293-300. doi: 10.1007/s11010-015-2562-4 PMID: 26346163
  21. Bu, H.Q.; Liu, D.L.; Wei, W.T.; Chen, L.; Huang, H.; Li, Y.; Cui, J.H. Oridonin induces apoptosis in SW1990 pancreatic cancer cells via p53- and caspase-dependent induction of p38 MAPK. Oncol. Rep., 2014, 31(2), 975-982. doi: 10.3892/or.2013.2888 PMID: 24297112
  22. Tian, L.; Xie, K.; Sheng, D.; Wan, X.; Zhu, G. Antiangiogenic effects of oridonin. BMC Complement. Altern. Med., 2017, 17(1), 192. doi: 10.1186/s12906-017-1706-3 PMID: 28376864
  23. Yang, Q.; Ma, W.; Yu, K.; Zhang, Q.; Ye, Z.; Xia, W.; Li, S. Oridonin suppresses human gastric cancer growth in vitro and in vivovia Inhibition of VEGF, Integrin β3, and PCNA. Biol. Pharm. Bull., 2020, 43(7), 1035-1045. doi: 10.1248/bpb.b19-00839 PMID: 32612067
  24. Xu, L.; Bi, Y.; Xu, Y.; Zhang, Z.; Xu, W.; Zhang, S.; Chen, J. Oridonin inhibits the migration and epithelial-to-mesenchymal transition of small cell lung cancer cells by suppressing FAK-ERK1/2 signalling pathway. J. Cell. Mol. Med., 2020, 24(8), 4480-4493. doi: 10.1111/jcmm.15106 PMID: 32168416
  25. Sun, Y.; Jiang, X.; Lu, Y.; Zhu, J.; Yu, L.; Ma, B.; Zhang, Q. Oridonin prevents epithelial-mesenchymal transition and TGF-β1-induced epithelial-mesenchymal transition by inhibiting TGF-β1/Smad2/3 in osteosarcoma. Chem. Biol. Interact., 2018, 296, 57-64. doi: 10.1016/j.cbi.2018.09.013 PMID: 30243739
  26. Liu, Q.Q.; Chen, K.; Ye, Q.; Jiang, X.H.; Sun, Y.W. Oridonin inhibits pancreatic cancer cell migration and epithelial-mesenchymal transition by suppressing Wnt/β-catenin signaling pathway. Cancer Cell Int., 2016, 16(1), 57. doi: 10.1186/s12935-016-0336-z PMID: 27453691
  27. Li, C.Y.; Wang, Q.; Shen, S.; Wei, X.L.; Li, G.X. Oridonin inhibits migration, invasion, adhesion and TGF-β1-induced epithelial-mesenchymal transition of melanoma cells by inhibiting the activity of PI3K/Akt/GSK-3β signaling pathway. Oncol. Lett., 2018, 15(1), 1362-1372. PMID: 29399187
  28. Du, Y.; Zhang, J.; Yan, S.; Tao, Z.; Wang, C.; Huang, M.; Zhang, X. Oridonin inhibits the proliferation, migration and invasion of human osteosarcoma cells via suppression of matrix metalloproteinase expression and STAT3 signalling pathway. J. BUON, 2019, 24(3), 1175-1180. PMID: 31424676
  29. Chen, K.; Ye, J.; Qi, L.; Liao, Y.; Li, R.; Song, S.; Zhou, C.; Feng, R.; Zhai, W. Oridonin inhibits hypoxia-induced epithelial–mesenchymal transition and cell migration by the hypoxia-inducible factor-1α/matrix metallopeptidase-9 signal pathway in gallbladder cancer. Anticancer Drugs, 2019, 30(9), 925-932. doi: 10.1097/CAD.0000000000000797 PMID: 31517732
  30. Santavanond, J.P.; Rutter, S.F.; Atkin-Smith, G.K.; Poon, I.K.H. Apoptotic bodies: Mechanism of formation, isolation and functional relevance. Subcell. Biochem., 2021, 97, 61-88. doi: 10.1007/978-3-030-67171-6_4 PMID: 33779914
  31. Jeon, M.Y.; Seo, S.U.; Woo, S.M.; Min, K.; Byun, H.S.; Hur, G.M.; Kang, S.C.; Kwon, T.K. Oridonin enhances TRAIL-induced apoptosis through GALNT14-mediated DR5 glycosylation. Biochimie., 2019, 165, 108-114. doi: 10.1016/j.biochi.2019.07.015 PMID: 31336136
  32. Gu, Z.; Wang, X.; Qi, R.; Wei, L.; Huo, Y.; Ma, Y.; Shi, L.; Chang, Y.; Li, G.; Zhou, L. Oridonin induces apoptosis in uveal melanoma cells by upregulation of Bim and downregulation of Fatty Acid Synthase. Biochem. Biophys. Res. Commun., 2015, 457(2), 187-193. doi: 10.1016/j.bbrc.2014.12.086 PMID: 25545058
  33. Lu, Y.; Sun, Y.; Zhu, J.; Yu, L.; Jiang, X.; Zhang, J.; Dong, X.; Ma, B.; Zhang, Q. Oridonin exerts anticancer effect on osteosarcoma by activating PPAR-γ and inhibiting Nrf2 pathway. Cell Death Dis., 2018, 9(1), 15. doi: 10.1038/s41419-017-0031-6 PMID: 29323103
  34. Gao, S.; Tan, H.; Zhu, N.; Gao, H.; Lv, C.; Gang, J.; Ji, Y. Oridonin induces apoptosis through the mitochondrial pathway in human gastric cancer SGC-7901 cells. Int. J. Oncol., 2016, 48(6), 2453-2460. doi: 10.3892/ijo.2016.3479 PMID: 27082253
  35. Jiang, J.H.; Pi, J.; Jin, H.; Cai, J.Y. Oridonin-induced mitochondria-dependent apoptosis in esophageal cancer cells by inhibiting PI3K/AKT/mTOR and Ras/Raf pathways. J. Cell. Biochem., 2019, 120(3), 3736-3746. doi: 10.1002/jcb.27654 PMID: 30229997
  36. Kou, B.; Yang, Y.; Bai, Y.E.; Shi, Y.H.; Gao, R.X.; Yang, F.L.; Zhang, S.Q.; Liu, W. Oridonin induces apoptosis of laryngeal carcinoma via endoplasmic reticulum stress. Cancer Manag. Res., 2020, 12, 8387-8396. doi: 10.2147/CMAR.S271759 PMID: 32982432
  37. Yao, Z.; Xie, F.; Li, M.; Liang, Z.; Xu, W.; Yang, J.; Liu, C.; Li, H.; Zhou, H.; Qu, L.H. Oridonin induces autophagy via inhibition of glucose metabolism in p53-mutated colorectal cancer cells. Cell Death Dis., 2017, 8(2), e2633. doi: 10.1038/cddis.2017.35 PMID: 28230866
  38. Chang, H.; Zou, Z. Targeting autophagy to overcome drug resistance: Further developments. J. Hematol. Oncol., 2020, 13(1), 159. doi: 10.1186/s13045-020-01000-2 PMID: 33239065
  39. Mizushima, N.; Levine, B. Autophagy in human diseases. N. Engl. J. Med., 2020, 383(16), 1564-1576. doi: 10.1056/NEJMra2022774 PMID: 33053285
  40. Cao, S.; Huang, Y.; Zhang, Q.; Lu, F.; Donkor, P.O.; Zhu, Y.; Qiu, F.; Kang, N. Molecular mechanisms of apoptosis and autophagy elicited by combined treatment with oridonin and cetuximab in laryngeal squamous cell carcinoma. Apoptosis, 2019, 24(1-2), 33-45. doi: 10.1007/s10495-018-1497-0 PMID: 30430397
  41. Bu, H.; Liu, D.; Zhang, G.; Chen, L.; Song, Z. AMPK/mTOR/ULK1 Axis-mediated pathway participates in apoptosis and autophagy induction by oridonin in colon cancer DLD-1 Cells. OncoTargets Ther., 2020, 13, 8533-8545. doi: 10.2147/OTT.S262022 PMID: 32904616
  42. Yang, H.; Gao, Y.; Fan, X.; Liu, X.; Peng, L.; Ci, X. Oridonin sensitizes cisplatin-induced apoptosis via AMPK/Akt/mTOR-Dependent autophagosome accumulation in A549 Cells. Front. Oncol., 2019, 9, 769. doi: 10.3389/fonc.2019.00769 PMID: 31475112
  43. Li, D.; Cui, Q.; Chen, S.; Wu, L.; Tashiro, S.; Onodera, S.; Ikejima, T. Inactivation of ras and changes of mitochondrial membrane potential contribute to oridonin-induced autophagy in a431 cells. J. Pharmacol. Sci., 2007, 105(1), 22-33. doi: 10.1254/jphs.FPJ06022X PMID: 17895587
  44. Fuloria, S.; Subramaniyan, V.; Karupiah, S.; Kumari, U.; Sathasivam, K.; Meenakshi, D.U.; Wu, Y.S.; Sekar, M.; Chitranshi, N.; Malviya, R.; Sudhakar, K.; Bajaj, S.; Fuloria, N.K. Comprehensive review of methodology to detect reactive oxygen species (ROS) in mammalian species and establish its relationship with antioxidants and cancer. Antioxidants, 2021, 10(1), 128. doi: 10.3390/antiox10010128 PMID: 33477494
  45. Fan, X.; Xie, M.; Zhao, F.; Li, J.; Fan, C.; Zheng, H.; Wei, Z.; Ci, X.; Zhang, S. Daphnetin triggers ROS-induced cell death and induces cytoprotective autophagy by modulating the AMPK/Akt/mTOR pathway in ovarian cancer. Phytomedicine, 2021, 82, 153465. doi: 10.1016/j.phymed.2021.153465 PMID: 33486268
  46. Pathania, D.; Sechi, M.; Palomba, M.; Sanna, V.; Berrettini, F.; Sias, A.; Taheri, L.; Neamati, N. Design and discovery of novel quinazolinedione-based redox modulators as therapies for pancreatic cancer. Biochim. Biophys. Acta, Gen. Subj., 2014, 1840(1), 332-343. doi: 10.1016/j.bbagen.2013.08.005 PMID: 23954204
  47. Oh, H.N.; Seo, J.H.; Lee, M.H.; Yoon, G.; Cho, S.S.; Liu, K.; Choi, H.; Oh, K.B.; Cho, Y.S.; Kim, H.; Han, A.L.; Chae, J.I.; Shim, J.H. Oridonin induces apoptosis in oral squamous cell carcinoma probably through the generation of reactive oxygen species and the p38/JNK MAPK pathway. Int. J. Oncol., 2018, 52(5), 1749-1759. doi: 10.3892/ijo.2018.4319 PMID: 29568920
  48. Zhang, D.; Zhou, Q.; Huang, D.; He, L.; Zhang, H.; Hu, B.; Peng, H.; Ren, D. ROS/JNK/c-Jun axis is involved in oridonin-induced caspase-dependent apoptosis in human colorectal cancer cells. Biochem. Biophys. Res. Commun., 2019, 513(3), 594-601. doi: 10.1016/j.bbrc.2019.04.011 PMID: 30981511
  49. Xue, D.; Zhou, X.; Qiu, J. Emerging role of NRF2 in ROS-mediated tumor chemoresistance. Biomed. Pharmacother., 2020, 131, 110676. doi: 10.1016/j.biopha.2020.110676 PMID: 32858502
  50. Wee, P.; Wang, Z. Epidermal growth factor receptor cell proliferation signaling pathways. Cancers, 2017, 9(5), 52. doi: 10.3390/cancers9050052 PMID: 28513565
  51. Sigismund, S.; Avanzato, D.; Lanzetti, L. Emerging functions of the EGFR in cancer. Mol. Oncol., 2018, 12(1), 3-20. doi: 10.1002/1878-0261.12155 PMID: 29124875
  52. Wu, M.; Zhang, P. EGFR-mediated autophagy in tumourigenesis and therapeutic resistance. Cancer Lett., 2020, 469, 207-216. doi: 10.1016/j.canlet.2019.10.030 PMID: 31639425
  53. Tumbrink, H.L.; Heimsoeth, A.; Sos, M.L. The next tier of EGFR resistance mutations in lung cancer. Oncogene, 2021, 40(1), 1-11. doi: 10.1038/s41388-020-01510-w PMID: 33060857
  54. Sidorov, M.; Dighe, P.; Woo, R.W.L.; Rodriguez-Brotons, A.; Chen, M.; Ice, R.J.; Vaquero, E.; Jian, D.; Desprez, P.Y.; Nosrati, M.; Galvez, L.; Leng, L.; Dickinson, L.; Kashani-Sabet, M.; McAllister, S.D.; Soroceanu, L. Dual targeting of EGFR and MTOR pathways inhibits glioblastoma growth by modulating the tumor microenvironment. Cells, 2023, 12(4), 547. doi: 10.3390/cells12040547 PMID: 36831214
  55. Kang, N.; Cao, S.; Jiang, B.; Zhang, Q.; Donkor, P.O.; Zhu, Y.; Qiu, F.; Gao, X. Cetuximab enhances oridonin-induced apoptosis through mitochondrial pathway and endoplasmic reticulum stress in laryngeal squamous cell carcinoma cells. Toxicol. In vitro, 2020, 67, 104885. doi: 10.1016/j.tiv.2020.104885 PMID: 32407876
  56. Li, D.; Wu, L.; Tashiro, S.; Onodera, S.; Ikejima, T. Oridonin-induced A431 cell apoptosis partially through blockage of the Ras/Raf/ERK signal pathway. J. Pharmacol. Sci., 2007, 103(1), 56-66. doi: 10.1254/jphs.FPJ06016X PMID: 17251686
  57. Xiao, X.; He, Z.; Cao, W.; Cai, F.; Zhang, L.; Huang, Q.; Fan, C.; Duan, C.; Wang, X.; Wang, J.; Liu, Y. Oridonin inhibits gefitinib-resistant lung cancer cells by suppressing EGFR/ERK/MMP-12 and CIP2A/Akt signaling pathways. Int. J. Oncol., 2016, 48(6), 2608-2618. doi: 10.3892/ijo.2016.3488 PMID: 27082429
  58. Pi, J.; Jiang, J.; Cai, H.; Yang, F.; Jin, H.; Yang, P.; Cai, J.; Chen, Z.W. GE11 peptide conjugated selenium nanoparticles for EGFR targeted oridonin delivery to achieve enhanced anticancer efficacy by inhibiting EGFR-mediated PI3K/AKT and Ras/Raf/MEK/ERK pathways. Drug Deliv., 2017, 24(1), 1549-1564. doi: 10.1080/10717544.2017.1386729 PMID: 29019267
  59. Verzella, D.; Pescatore, A.; Capece, D.; Vecchiotti, D.; Ursini, M.V.; Franzoso, G.; Alesse, E.; Zazzeroni, F. Life, death, and autophagy in cancer: NF-κB turns up everywhere. Cell Death Dis., 2020, 11(3), 210. doi: 10.1038/s41419-020-2399-y PMID: 32231206
  60. Leung, C.H.; Grill, S.P.; Lam, W.; Han, Q.B.; Sun, H.D.; Cheng, Y.C. Novel mechanism of inhibition of nuclear factor-kappa B DNA-binding activity by diterpenoids isolated from Isodon rubescens. Mol. Pharmacol., 2005, 68(2), 286-297. doi: 10.1124/mol.105.012765 PMID: 15872117
  61. Dong, X.; Liu, F.; Li, M. Inhibition of nuclear factor κB transcription activity drives a synergistic effect of cisplatin and oridonin on HepG2 human hepatocellular carcinoma cells. Anticancer Drugs, 2016, 27(4), 286-299. doi: 10.1097/CAD.0000000000000329 PMID: 26704389
  62. Xu, X.; Lai, Y.; Hua, Z.C. Apoptosis and apoptotic body: Disease message and therapeutic target potentials. Biosci. Rep., 2019, 39(1), BSR20180992. doi: 10.1042/BSR20180992 PMID: 30530866
  63. Bao, R.; Shu, Y.; Wu, X.; Weng, H.; Ding, Q.; Cao, Y.; Li, M.; Mu, J.; Wu, W.; Ding, Q.; Tan, Z.; Liu, T.; Jiang, L.; Hu, Y.; Gu, J.; Liu, Y. Oridonin induces apoptosis and cell cycle arrest of gallbladder cancer cells via the mitochondrial pathway. BMC Cancer, 2014, 14(1), 217. doi: 10.1186/1471-2407-14-217 PMID: 24655726
  64. Ikezoe, T.; Yang, Y.; Bandobashi, K.; Saito, T.; Takemoto, S.; Machida, H.; Togitani, K.; Koeffler, H.P.; Taguchi, H. Oridonin, a diterpenoid purified from Rabdosia rubescens, inhibits the proliferation of cells from lymphoid malignancies in association with blockade of the NF-κB signal pathways. Mol. Cancer Ther., 2005, 4(4), 578-586. doi: 10.1158/1535-7163.MCT-04-0277 PMID: 15827331
  65. O’Donnell, J.S.; Massi, D.; Teng, M.W.L.; Mandala, M. PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux. Semin. Cancer Biol., 2018, 48, 91-103. doi: 10.1016/j.semcancer.2017.04.015 PMID: 28467889
  66. Janku, F.; Yap, T.A.; Meric-Bernstam, F. Targeting the PI3K pathway in cancer: Are we making headway? Nat. Rev. Clin. Oncol., 2018, 15(5), 273-291. doi: 10.1038/nrclinonc.2018.28 PMID: 29508857
  67. Donohoe, F.; Wilkinson, M.; Baxter, E.; Brennan, D.J. Mitogen-activated protein kinase (MAPK) and obesity-related cancer. Int. J. Mol. Sci., 2020, 21(4), 1241. doi: 10.3390/ijms21041241 PMID: 32069845
  68. Liu, R.X.; Ma, Y.; Hu, X.L.; Ren, W.Y.; Liao, Y.P.; Wang, H.; Zhu, J.H.; Wu, K.; He, B.C.; Sun, W.J. Anticancer effects of oridonin on colon cancer are mediated via BMP7/p38 MAPK/p53 signaling. Int. J. Oncol., 2018, 53(5), 2091-2101. doi: 10.3892/ijo.2018.4527 PMID: 30132514
  69. Zhang, C.L.; Wu, L.J.; Tashiro, S.I.; Onodera, S.; Ikejima, T. Oridonin induced A375-S2 cell apoptosis via BAX-regulated caspase pathway activation, dependent on the cytochrome C/CASPASE-9 apoptosome. J. Asian Nat. Prod. Res., 2004, 6(2), 127-138. doi: 10.1080/1028602031000147375 PMID: 15008459
  70. Zhang, C.L.; Wu, L.J.; Tashiro, S.; Onodera, S.; Ikejima, T. Oridonin induces a caspase-independent but mitochondria- and MAPK-dependent cell death in the murine fibrosarcoma cell line L929. Biol. Pharm. Bull., 2004, 27(10), 1527-1531. doi: 10.1248/bpb.27.1527 PMID: 15467189
  71. Cai, D.; Jin, H.; Xiong, Q.X.; Liu, W.G.; Gao, Z.; Gu, G.; Qiu, Y. ER stress and ASK1-JNK activation contribute to oridonin-induced apoptosis and growth inhibition in cultured human hepatoblastoma HuH-6 cells. Mol. Cell. Biochem., 2013, 379(1-2), 161-169. doi: 10.1007/s11010-013-1638-2 PMID: 23580093
  72. Liang, J.; Wang, W.; Wei, L.; Gao, S.; Wang, Y. Oridonin inhibits growth and induces apoptosis of human neurocytoma cells via the Wnt/β-catenin pathway. Oncol. Lett., 2018, 16(3), 3333-3340. doi: 10.3892/ol.2018.8977 PMID: 30127932
  73. Xia, S.; Zhang, X.; Li, C.; Guan, H. Oridonin inhibits breast cancer growth and metastasis through blocking the Notch signaling. Saudi Pharm. J., 2017, 25(4), 638-643. doi: 10.1016/j.jsps.2017.04.037 PMID: 28579904
  74. Perez-Fidalgo, J.A.; Ortega, B.; Simon, S.; Samartzis, E.P.; Boussios, S. NOTCH signalling in ovarian cancer angiogenesis. Ann. Transl. Med., 2020, 8(24), 1705. doi: 10.21037/atm-20-4497 PMID: 33490217
  75. Dong, Y.; Zhang, T.; Li, J.; Deng, H.; Song, Y.; Zhai, D.; Peng, Y.; Lu, X.; Liu, M.; Zhao, Y.; Yi, Z. Oridonin inhibits tumor growth and metastasis through anti-angiogenesis by blocking the notch signaling. PLoS One, 2014, 9(12), e113830. doi: 10.1371/journal.pone.0113830 PMID: 25485753
  76. Liu, H.; Qian, C.; Shen, Z. Anti-tumor activity of oridonin on SNU-5 subcutaneous xenograft model via regulation of c-Met pathway. Tumour Biol., 2014, 35(9), 9139-9146. doi: 10.1007/s13277-014-2178-4 PMID: 24916572
  77. Liu, Y.; Liu, J.H.; Chai, K.; Tashiro, S.I.; Onodera, S.; Ikejima, T. Inhibition of c-Met promoted apoptosis, autophagy and loss of the mitochondrial transmembrane potential in oridonin-induced A549 lung cancer cells. J. Pharm. Pharmacol., 2013, 65(11), 1622-1642. doi: 10.1111/jphp.12140 PMID: 24102522
  78. Duan, D.; Wang, X.; Feng, X.; Pan, D.; Wang, L.; Wang, Y. Oridonin induces oxidative stress-mediated cancer cells apoptosis via targeting thioredoxin reductase. Curr. Pharm. Biotechnol., 2022, 23(14), 1647-1657. doi: 10.2174/1389201023666211217151955 PMID: 34923938
  79. Liu, W.; Wang, X.; Wang, L.; Mei, Y.; Yun, Y.; Yao, X.; Chen, Q.; Zhou, J.; Kou, B. Oridonin represses epithelial-mesenchymal transition and angiogenesis of thyroid cancer via downregulating JAK2/STAT3 signaling. Int. J. Med. Sci., 2022, 19(6), 965-974. doi: 10.7150/ijms.70733 PMID: 35813296
  80. Cao, Y.; Wei, W.; Zhang, N.; Yu, Q.; Xu, W.B.; Yu, W.J.; Chen, G.Q.; Wu, Y.L.; Yan, H. Oridonin stabilizes retinoic acid receptor alpha through ROS-activated NF-κB signaling. BMC Cancer., 2015, 15(1), 248. doi: 10.1186/s12885-015-1219-8 PMID: 25886043
  81. Wang, S.; Zhong, Z.; Wan, J.; Tan, W.; Wu, G.; Chen, M.; Wang, Y. Oridonin induces apoptosis, inhibits migration and invasion on highly-metastatic human breast cancer cells. Am. J. Chin. Med., 2013, 41(1), 177-196. doi: 10.1142/S0192415X13500134 PMID: 23336515
  82. Zeng, R.; Chen, Y.; Zhao, S.; Cui, G. Autophagy counteracts apoptosis in human multiple myeloma cells exposed to oridonin in vitrovia regulating intracellular ROS and SIRT1. Acta Pharmacol. Sin., 2012, 33(1), 91-100. doi: 10.1038/aps.2011.143 PMID: 22158107
  83. Xu, W.; Sun, J.; Zhang, T.; Ma, B.; Cui, S.; Chen, D.; He, Z. Pharmacokinetic behaviors and oral bioavailability of oridonin in rat plasma. Acta Pharmacol. Sin., 2006, 27(12), 1642-1646. doi: 10.1111/j.1745-7254.2006.00440.x PMID: 17112421
  84. Ding, C.; Zhang, Y.; Chen, H.; Yang, Z.; Wild, C.; Chu, L.; Liu, H.; Shen, Q.; Zhou, J. Novel nitrogen-enriched oridonin analogues with thiazole-fused A-ring: protecting group-free synthesis, enhanced anticancer profile, and improved aqueous solubility. J. Med. Chem., 2013, 56(12), 5048-5058. doi: 10.1021/jm400367n PMID: 23746196
  85. Zhang, Y.; Wang, S.; Dai, M.; Nai, J.; Zhu, L.; Sheng, H. Solubility and bioavailability enhancement of oridonin: A review. Molecules, 2020, 25(2), 332. doi: 10.3390/molecules25020332 PMID: 31947574
  86. Xu, S.; Yao, H.; Luo, S.; Zhang, Y.K.; Yang, D.H.; Li, D.; Wang, G.; Hu, M.; Qiu, Y.; Wu, X.; Yao, H.; Xie, W.; Chen, Z.S.; Xu, J. A novel potent anticancer compound optimized from a natural oridonin scaffold induces apoptosis and cell cycle arrest through the mitochondrial pathway. J. Med. Chem., 2017, 60(4), 1449-1468. doi: 10.1021/acs.jmedchem.6b01652 PMID: 28165738
  87. Zhou, X.; Zhang, X.; Ye, Y.; Zhang, T.; Wang, H.; Ma, Z.; Wu, B. Nanostructured lipid carriers used for oral delivery of oridonin: An effect of ligand modification on absorption. Int. J. Pharm., 2015, 479(2), 391-398. doi: 10.1016/j.ijpharm.2014.12.068 PMID: 25556104
  88. Lin, F.; Zhang, X.; Zhang, Y.; Wang, J. Preparation, characterization, and pharmacokinetics of oridonin-loaded liposomes. Biomed. Chromatogr., 2023, 37(5), e5603. doi: 10.1002/bmc.5603 PMID: 36781382

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Bentham Science Publishers